Triple
T22796790
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CDK6 |
E564269
|
entity |
| Predicate | isDrugTargetOf |
P37016
|
FINISHED |
| Object | dalpiciclib |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: dalpiciclib | Statement: [CDK6, isDrugTargetOf, dalpiciclib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: dalpiciclib Context triple: [CDK6, isDrugTargetOf, dalpiciclib]
-
A.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: dalpiciclib Target entity description: Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
-
A.
trilaciclib
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
Created at: April 17, 2026, 3:30 p.m.